Phase 4 N=28 Drug-Drug Interaction of Darunavir/Ritonavir on Pitavastatin
Healthy
Primary: NK-104 AUC — 192.00 ng * h/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=25 Drug-drug Interaction Study
Pompe Disease
Primary: Number Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs) — 0; 0; 0; 1 Participants
Phase 1 N=14 Drug-drug Interaction Study of Gepotidacin
Infections, Bacterial
Primary: Cohort 1: Maximum Observed Concentration (Cmax) of Gepotidacin in Plasma — 4.817; 4.548 Micrograms per milliliter
Phase 4 N=28 Drug-Drug Interaction of Cardizem LA (Diltiazem Hydrochloride) on Pitavastatin
Healthy
Primary: NK-104 AUC — 208.92 ng * h/mL
Phase 1 N=36 Drug Interaction Study With Dabigatran Etexilate and Dronedarone in Healthy Subjects
Healthy
Primary: Total Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞) — 1160; 2520; 1440; 2570 ng*hr/mL — p=1.0000
Phase 1 N=42 SSP-002358 Drug Interaction Study With Omeprazole
Healthy
Primary: Maximum Plasma Concentration (Cmax) for SSP-002358 — 3.89; 4.12 ng/ml
Phase 4 N=24 Drug-Drug Interaction of Lopinavir/Ritonavir on Pitavastatin
Healthy Volunteers
Primary: Area Under the Curve From Time 0 to Tau (AUC 0-τ) — 113.92 ng•h/mL
Phase 1 N=12 Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir
Healthy Participant
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-07321332 — 2210; 1300 nanogram per milliliter (ng/mL) — p=0.05
Phase 1 N=24 Drug-Drug Interaction Study Between Colchicine and Diltiazem ER
Healthy; Adult; Volunteer; Colchicine; Pharmacokinetics; Diltiazem; Cytochrome p450 3A4; P-glycoprotein
Primary: Maximum Plasma Concentration (Cmax) — 2,172.32; 2,802.90 pg/mL
Phase 1 N=24 PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants
Healthy Participants
Primary: Plasma Dabigatran (Total) PK Parameters (PF-07321332/Ritonavir Co-administered With Dabigatran [Treatment 2]): Maximum Plasma Concentration (Cmax) — 71.87; 154.1 ng/mL
Phase 1 N=28 Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug)
Drug Drug Interaction
Primary: Dogoxin Plasma Data for Cmax — 1530.188; 2432.908 pg/mL
Phase 1 N=19 Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)
HIV Infections
Primary: Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval at Steady State (AUC[0-tau]) of GSK3640254 — 27.03; 30.70…
Phase 1 N=56 Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
Advanced Solid Tumors · Metastatic Melanoma
Primary: Maximum Concentration (Cmax) of Plasma Midazolam on Day -7, Day 1, and Day 14 — 9.45; 11.1; 2.44 nanograms per milliliter (ng/mL)
Phase 1 N=30 Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz
Healthy
Primary: Maximum Plasma Concentration (Cmax) of Efavirenz — 2,461.58; 2,384.79 ng/mL
Phase 1 N=72 Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
Hepatitis C, Chronic
Primary: Cmax of Faldaprevir (BI 201335) — 3520; NA; 8780; 9950 ng/mL — p=1.0000
Phase 4 N=48 Drug-Drug Interaction Study to Assess the Effects of Steady State Pitavastatin 4 mg or Rosuvastatin 40 mg on Steady-State Warfarin in Healthy Adult Volunteers
Healthy
Primary: Percent Mean Change From Baseline of International Normalized Ratio (INR) — 0.0452; 0.1605 percent change
Phase 1 N=28 A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults
Pulmonary Disease · Tuberculosis, Pulmonary · Tuberculosis
Primary: TBAJ-876 Effect on the Pharmacokinetics of the CYP-3A4 Substrate Midazolam in Healthy Adult Subjects: Pharmacokinetic Parameters AUC — 22.64; 25.22; 24.28; 25.68 ng.hr/mL
Phase 1 N=40 Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates
Healthy
Primary: Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Digoxin — 15.8; 18.7 Hour*nanogram per milliliter (h*ng/mL)
Phase 1 N=24 Drug-Drug Interaction Study of Qualaquin and Midazolam
Healthy
Primary: Maximum Serum Concentration (Cmax) — 12.0435; 4.6907; 4432.4089; 12.5585 ng/ml
Phase 1 N=62 Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine
Healthy
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) for Amoxicillin — 27.8; 28.3 h*ug/ml
Phase 1 N=48 Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor
Healthy
Primary: Total Dabigatran: Area Under the Concentration-time Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss) — 551; 817; 689; 660 ng*h/mL — p=0.9456
N/A N=10 Drug Interaction Study of Rifampin and Warfarin in Healthy Volunteers.
Healthy
Primary: S- and R- Enantiomers of Warfarin (S-warfarin and R-warfarin) Area Under the Plasma Concentration-time Curve (AUC) From 0 to 12 Hours. — 2,250; 2,230; 2,850; 2,930 ng/ml*h
Phase 4 N=44 Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
Smallpox
Primary: AUC0-inf — 16300; 21600; 21000; 19500 ng*h/mL
Phase 1 N=30 Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine
Healthy
Primary: Area Under the Plasma Concentration Curve (AUC) at Steady State for Metronidazole — 217686; 215809 ng*h/ml
Phase 1 N=12 Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants
Healthy Participant
Primary: Maximum Observed Concentration (Cmax) of PF-07321332 — 4678; 5546 ng/mL — p=0.05
Phase 1 N=60 Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers
Healthy
Primary: Plasma Dipyridamole Maximum Concentration (Cmax) — 2750; 2550; 2550 nanogram/milliliter
Phase 1 N=24 Drug-Drug Interaction Study Between Colchicine and Ketoconazole
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2,779.08; 5,266.92 pg/mL
Phase 1 N=17 A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects
Drug Interaction Potentiation
Primary: Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam in Healthy Subjects (Cmax) — 12.4; 13.0 ng/mL
Phase 1 N=40 Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Metformin — 5033.8718; 6142.2821; 6090.7932 nanogram*hour per…
Phase 1 N=21 A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
Healthy Subjects
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUCt) of Apremilast — 3070; 2940; 850 ng*h/mL